論文 - 詳細
| RRC ID | 58782 |
|---|---|
| 著者 | Kuchitsu Y, Nagashio R, Igawa S, Kusuhara S, Tsuchiya B, Ichinoe M, Satoh Y, Naoki K, Murakumo Y, Saegusa M, Sato Y. |
| タイトル | TRAP1 is a predictive biomarker of platinum-based adjuvant chemotherapy benefits in patients with resected lung adenocarcinoma. |
| ジャーナル | Biomed Res |
| Abstract |
Platinum-based adjuvant chemotherapy after complete resection has become a standard treatment for patients with stage II to IIIA non-small cell lung cancer; however, not all patients exhibit survival benefits. Therefore, the development of predictive biomarkers for selecting a subgroup of patients who may show improved survival after these treatments is important. Among the 42 proteins identified here using a proteomics analysis that were recognized by autoantibodies in pretreated sera from patients with lung adenocarcinoma who received platinum-based adjuvant chemotherapy, the tumor necrosis factor-receptor-associated protein 1 (TRAP1) was detected in patients with a short disease-free survival. TRAP1 expression was immunohistochemically analyzed in 64 patients with completely resected stage II and IIIA lung adenocarcinoma treated with platinum-based adjuvant chemotherapy. TRAP1 expression was significantly associated with higher p-TNM stage (P = 0.005) and lymph node metastasis (P = 0.017). Moreover, TRAP1 expression was significantly correlated with a shorter disease-free survival (P = 0.028). Furthermore, TRAP1-siRNA-treated LC-2/ad cells derived from lung adenocarcinoma exhibited significantly reduced proliferation and increased sensitivity to cisplatin. These results suggest that TRAP1 expression is a valuable biomarker for predicting the poor survival of platinum-based adjuvant chemotherapy in patients with resected lung adenocarcinoma. |
| 巻・号 | 41(1) |
| ページ | 53-65 |
| 公開日 | 2020-1-1 |
| DOI | 10.2220/biomedres.41.53 |
| PMID | 32092740 |
| MeSH | A549 Cells Adenocarcinoma of Lung / drug therapy* Adenocarcinoma of Lung / surgery* Adult Aged Biomarkers, Tumor / metabolism* Chemotherapy, Adjuvant / methods* Cisplatin / pharmacology Disease-Free Survival Drug Resistance, Neoplasm Electrophoresis, Gel, Two-Dimensional Female HSP90 Heat-Shock Proteins / metabolism* Humans Immunohistochemistry Lung Neoplasms / drug therapy* Lung Neoplasms / surgery* Lymphatic Metastasis Male Middle Aged Proteomics / methods RNA, Small Interfering / metabolism Retrospective Studies |
| IF | 1.429 |
| 引用数 | 1 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | X(Twitter) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | A549, LC-2/ad(RCB0440) |